IntegenX, based in Pleasanton, California, develops Rapid human DNA identification technology that integrates advanced fluidics, optics and biochemistry. Led by Chief Operating Officer David V. Smith, the company produces products for DNA-based human identity testing. Its technology is targeted at forensics and law enforcement applications. The company announced a financing to support operations and working capital. The article reports a $10M venture loan as the company’s latest financing activity. No revenue or user metrics were disclosed in the article. IntegenX develops rapid human DNA identification technology and DNA sequencing library-preparation systems, including the RapidHIT 200 biometric sample-to-profile system. The RapidHIT 200 is designed to enable law enforcement, government agencies, and forensic laboratories to provide real-time human DNA analysis. The company also offers the Apollo 324 automated NGS library-prep system and GenTegra and GenPlate products for dry-state stabilization and room-temperature storage of DNA, RNA, whole blood, and biological fluids. Led by CEO Stevan Jovanovich, Ph.D., IntegenX plans to use new funding to accelerate development of its product pipeline and commercialize the RapidHIT 200 in domestic and international markets. Financially, the company secured $40M in a Series C financing announced in December 2011. IntegenX raised $15.6M in its second financing round and recently acquired GenVault Corporation. The company designs, manufactures and markets automated DNA- and RNA-based sample-preparation systems. The acquisition adds GenVault’s GenTegra™ products to IntegenX’s portfolio, enabling transport and storage of biosamples without refrigeration and preventing degradation. The capital will fund commercialization of the Apollo 324 System for next-generation sequencing library preparation and development of the Apollo 200 RapidHIT™ System for DNA-based human identification. It will also support worldwide marketing of GenTegra™ products to increase the quality and value of data produced by IntegenX’s integrated systems. IntegenX is led by President and CEO Stevan Jovanovich, Ph.D. Microchip Biotechnologies develops integrated systems for microsample preparation and analysis. Its core product is the Apollo 100 System, a sample preparation system for Sanger DNA cycle sequencing. The company plans to commercialize the Apollo 100 and to extend the Apollo platform into the rapidly growing Next-Generation Sequencing market. It is also targeting emerging markets in DNA-based human identification and forensics. To support these efforts, Microchip recently completed a significant financing round. The company is based in Pleasanton, California.

Total raised

$84M

Funding rounds

4

Latest round

Debt Financing

Latest activity

Sep 2014